Table 3.
Skeletal-related events in patients developing bone metastases during the five year study period
| Clodronate | Placebo | |
| Total number of patients | 530 | 539 |
| Skeletal-related event | ||
| Confirmed bone metastases | 51 (9.6%) % of bone | 73 (13.5%) % of bone |
| Radiation therapy | 24 (4.5%) (48%) | 47 (8.7%) (69%) |
| Non-vertebral fracture | 6 (1.1%) (2%) | 16 (2.9%) (22%) |
| Vertebral fracture | 6 (1.1%) (2%) | 14 (2.6%) (19%) |
| Hypercalcemia | 3 (0.5%) (1%) | 11 (2.0%) (15%) |
| Spinal cord compression | 2 (0.4%) (1%) | 5 (0.9%) (7%) |
| Bone surgery | 1 (0.2%) (1%) | 4 (0.7%) (5%) |
| Overall for 5 year study period1 (any skeletal event) | 29 (5.5%) (0.4%) | 53 (9.8%) (73%) |
1P < 0.01 versus placebo.